VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
IMAImageneBio Inc$5.43$61M
Research
Overview
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksIMARevenue History

IMA logoImageneBio Inc (IMA) Revenue History

Annual and quarterly revenue from 2018 to present

TTM Revenue$0▼ $800K vs FY2025
YoY Growth—
Q1 2026$0
Revenue CAGR
3Y-62.9%
→
5Y-38.6%
→
10Y—
Growth decelerating ↓
Best Fiscal Year$31.0M (2021)
Best Quarter$20.2M (Q4 2021)

IMA Revenue Over Time (2018–2025)

IMA Revenue Growth History

2 of 7 years with positive growth
Annual Revenue Growth · Each cell = one fiscal year
2018—
2019+1289.2%
2020-33.1%
2021+237.0%
2022-49.6%
2023-41.3%
2024-61.8%
2025-77.1%
FY2018 revenue growth
N/A
FY2019 revenue growth
+1289.2%
FY2020 revenue growth
-33.1%
FY2021 revenue growth
+237.0%
FY2022 revenue growth
-49.6%
FY2023 revenue growth
-41.3%
FY2024 revenue growth
-61.8%
FY2025 revenue growth
-77.1%
DeclineStrong growth
↓ 4-year revenue declineBest: +1289.2% (FY2019)Worst: -77.1% (FY2025)
Recent Quarterly Revenue & YoY Growth
QuarterRevenueYoY
Q1 2026$0—
Q4 2025$0—
Q3 2025$0—
Q2 2025$0—
Q1 2025$0—
Q4 2024$0-100.0%
Q3 2024$0-100.0%
Q2 2024$0-100.0%
Seasonal Revenue Pattern (fiscal quarters)
Q1
30%
Q2
12%
Q3
22%
Q4
36%

Multi-year avg. share of annual revenue by fiscal quarter

IMA Revenue Analysis (2018–2025)

Current Revenue & Growth

As of June 13, 2026, ImageneBio Inc (IMA) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q1 2026) recorded $0 in revenue

Historical Growth Trajectory

IMA's 5-year compound annual growth rate (CAGR) stands at -38.6%, indicating revenue contraction over this period. The 3-year CAGR of -62.9% is below the 5-year average, signalling a growth deceleration in recent years. ImageneBio Inc's highest annual revenue of $31.0 million was recorded in 2021.

Peer Comparison

Compared to Healthcare sector peers — including SRZN (-35.6% YoY), KYMR (-12.6% YoY), and ARQT (+95.3% YoY). Compare IMA vs SRZN →

IMA Revenue vs Peers

Revenue metrics vs comparable public companies

CompanyTTM RevenueYoY Growth5Y CAGROp. MarginCompare
IMA logoIMACurrent$0--38.6%-6056.4%
SRZN logoSRZN$3M-35.6%--1210.6%
KYMR logoKYMR$39M-12.6%+2.9%-891.3%
ARQT logoARQT$376M+95.3%--3.3%
PRTA logoPRTA$10M-58.0%+62.6%-1905.8%
Best in groupLowest in group

IMA Historical Revenue Data (2018–2025)

1–8 of 8 records
Year Revenue YoY % Gross Profit Gross Margin Op. Income Op. Margin
2025$800K-77.1%$-233,000-29.1%$-48,451,000-6056.4%
2024$3.5M-61.8%$3.5M100.0%$-37,000,000-1057.1%
2023$9.2M-41.3%$8.1M88.9%$-75,417,000-823.3%
2022$15.6M-49.6%$-48,703,000-311.8%$-70,904,000-454.0%
2021$31.0M+237.0%$-16,123,000-52.0%$-34,138,000-110.2%
2020$9.2M-33.1%$-35,653,000-387.8%$-44,519,000-484.2%
2019$13.8M+1289.2%$-11,185,000-81.3%$-18,492,000-134.5%
2018$990K-$-37,996,000-3838.0%$-40,894,000-4130.7%

What if you invested $1,000 in IMA back in 2018?

Total return with dividends reinvested · 8+ years of data

Calculate Returns

How much would $100/month in IMA be worth today?

Dollar cost averaging vs lump sum · see how regular investing compounds over time

Run the Numbers

Is IMA Undervalued Right Now?

DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.

View Valuation

IMA vs LLY — which is the better buy?

Side-by-side revenue, margins, P/E and 10-year returns vs Eli Lilly and Company.

Compare Now

IMA — Frequently Asked Questions

Quick answers to the most common questions about buying IMA stock.

Is IMA's revenue growth accelerating or slowing?

IMA TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: -38.6%.

What is IMA's revenue history from 2018 to 2026?

ImageneBio Inc (IMA) revenue history spans 2018 to 2026. TTM revenue as of 2026 is $0.00, growing at N/A YoY. The 5-year CAGR is -38.6%. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.

What is IMA's long-term revenue growth rate (CAGR)?

ImageneBio Inc's 5-year revenue CAGR of -38.6% reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of N/A is in line with this long-term average. CAGR is the most reliable measure of sustained revenue momentum for IMA.

Why does IMA's quarterly revenue fluctuate?

IMA quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. ImageneBio Inc's revenue data from 2018 to 2026 shows full historical quarterly detail on this page.

How is IMA's revenue distributed by segment?

IMA reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.

How does IMA's revenue compare to industry peers?

ImageneBio Inc (IMA) with TTM revenue of $0.00 and N/A YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.